Chinese cardiovascular firm Sihuan heads for Hong Kong IPO
This article was originally published in Scrip
The Chinese company Sihuan Pharmaceutical Holdings Group is aiming to raise up to $816 million through an initial public offering in Hong Kong, which it will use mainly to fund mergers and acquisitions and to bolster R&D.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.